Jonn R. Beeson - 15 Aug 2023 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Role
Director
Signature
/s/ Amy E. Culbert, attorney-in-fact
Issuer symbol
XTNT
Transactions as of
15 Aug 2023
Net transactions value
$0
Form type
4
Filing time
17 Aug 2023, 16:18:49 UTC
Previous filing
16 May 2023
Next filing
19 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XTNT Common Stock Award $0 +145,180 +279% $0.000000 197,229 15 Aug 2023 Direct F1, F2
holding XTNT Common Stock 1,015,272 15 Aug 2023 The Platinum Legacy Trust, dated February 24, 2017, Jonn R. Beeson, Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XTNT Stock Option (right to buy) Award $0 +28,230 $0.000000 28,230 15 Aug 2023 Common Stock 28,230 $1.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.
F2 Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. 2023 Equity Incentive Plan and 52,049 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, all conditioned upon the Reporting Person remaining a director of Xtant through the vesting dates.
F3 This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.